Reduces gastric acid secretion.

New data now available.

1 Healing

Further experience in clinical trials confirms that 4-8 weeks 'Tagamet' treatment achieves remarkable results in duodenal ulcer,[1,2,3] gastric ulcer,[2,4,6] and reflux oesophagitis.[2,5]

Overall Experience	TAGAMET % healed	PLACEBO % healed
Duodenal Ulcer	77% of 803 patients	41% of 252 patients
Gastric Ulcer	74% of 130 patients	45% of 64 patients
Reflux Oesophagitis*	62% of 39 patients	9% of 23 patients

*includes oesophageal ulcers and erosions: complete healing or marked improvement.

In addition to complete healing (proven endoscopically), early and dramatic symptomatic relief is achieved in most patients. With its convenient dosage and low incidence of side effects, 'Tagamet' is well suited to everyday treatment.

2 Recurrence

A group of duodenal ulcer patients was followed for periods of up to 6 months after completing 4-6 weeks 'Tagamet' treatment. Preliminary results show that the incidence of relapse was no greater than in a similar group who had healed their ulcers on placebo.[2,7]

Artist's impression of H_2 receptor antagonist acting at receptor site in gastric mucosa.

3 Maintenance

377 chronic duodenal ulcer patients, who had healed their ulcers after 4-6 weeks treatment were entered into controlled, double-blind maintenance trials. They were maintained on 'Tagamet' or placebo therapy, at a reduced dosage, for periods of up to 6 months. Results from these ongoing studies have shown that only 5.7% of the 'Tagamet' group relapsed [7] compared with 42.1% of the group who were maintained on placebo.



References
1. Oral cimetidine in severe duodenal ulceration, (1977) Lancet, **i**, 4.
2. Data on file (March 1977), Smith Kline & French.
3. The effect of cimetidine on duodenal ulceration. (1977). The Second International Symposium on Histamine H_2 Receptor Antagonists. Excerpta Medica, p.260.
4. Treatment of gastric ulcer by cimetidine. (1977) ibid. p.287.
5. Cimetidine in the treatment of oesophagitis. (1977) ibid. p.297.
6. Healing of gastric ulcer during treatment with cimetidine. (1976) Lancet, **i**, 337.
7. Long-term treatment with cimetidine in duodenal ulceration (1977) Lancet, **i**, 900.

'Tagamet' (cimetidine) is available as 200mg film-coated tablets, 200mg/5ml syrup and 200mg/2ml ampoules.

Full prescribing information is available from Smith Kline & French Laboratories Limited, a SmithKline company, Welwyn Garden City, Hertfordshire, AL7 1EY
'Tagamet' is a trade mark.

SK&F

Tagamet

(cimetidine, SK&F)

H2

The H_2 receptor antagonist
Reduces gastric acid secretion

TG:AD 16

Advantages of Caved-(S) (deglycyrrhizinised liquorice) in the treatment of Peptic Ulcers

RELAPSE RATE

Caved-(S) has shown its effectiveness in preventing relapse and recurrence of duodenal ulcers.[1]

PROTECTION OF MUCOSAL BARRIER

It is now assumed that bile salts may play an important rôle in the pathogenesis of gastric ulcer by breaking the gastric mucosal barrier and allowing back diffusion of hydrogen ions.[2] The deglycyrrhizinised liquorice of Caved-(S) has been demonstrated to protect the gastric mucosa against the damaging effect of bile.[3]

ANTACIDS

Treatment of peptic ulcers with Caved-(S) gives the patient rapid symptomatic relief, and therefore additional antacids are not required.

Caved-(S) is an effective therapy for the treatment of peptic ulcers and is considerably lower in cost.

Caved-(S) – effective and low cost treatment for peptic ulcers and allied conditions.

Caved-(S) – dosage can be adjusted according to the severity of the condition.

Caved-(S) – does not require additional antacid therapy.

Caved-(S) – no reported side effects other than rare cases of mild diarrhoea.

REFERENCES
1. Tewari, S.N. and Wilson, A.K. (1973: The Practitioner, 210, 820.
2. Ivey, K.J. (1971): Gastroenterology, 61, 247.
3. Morris, T.J. et al (1974): Digestion, 11, 355.

TILLOTTS LABORATORIES, Henlow Trading Estate, Henlow, Beds. Tel. 0462 813933.

The new Fujinon Endoscopes



Pyser Limited are pleased to introduce the Fujinon range of flexible endoscopes for Upper and Lower Gastrointestinal Tract.

The small diameter forward viewing Oesophago Gastro Duodenoscope has four way tip control and can be angled to 180°. It also has twin light channels and Biopsy facilities.

Duodenoscopy and Cannulation are catered for with the 1360mm length Duodenoscope.

For the Colonoscopist there is a choice of three lengths, 1130mm, 1360mm and 1855mm all of 13mm diameter and having forcep control. All Conoloscopes are insulated for use with Diathermy.

The Fujinon range has been designed in co-operation with practising Endoscopists throughout the world and many of the irritating problems which occur in fibrescopes have been eliminated.

Air, water and suction are controlled by electronic micro-switches for simple trouble-free operation, powered by the low cost light source.

Automatic photography is available with a choice of 8mm cine or 35mm still from the Fuji camera range utilising the standard light source.

Fuji, one of the world's leading optical companies, have been producing fibre bundles for many years and the image quality of the Fujinon fibrescopes is unsurpassed.

Send for literature or a hospital demonstration — Fujinon fibrescopes have many other special features worth your attention — and are backed with after sales service by Pyser Ltd., a company with more than 50 years experience in the optical and scientific industry.

An important advance in Endoscope design

FUJINON

Sole UK Distributor: Pyser Ltd., Edenbridge, Kent

For full information please contact:
Pyser Ltd., Endoscope Division, 102 College Road, Harrow, Middlesex HA1 1BQ. Tel: 01-427 2278

THE CHALLENGE OF SUTURES

CONTINUOUS CLOSURE IN ABDOMINAL WOUNDS

Continuous monofilament closure in abdominal wounds is increasingly favoured by surgeons today. The introduction of a suture consisting of a strand of material formed into a loop eliminates the need for the first knot in a continuous suture line. ETHICON* have now produced a MERSUTURES* Eyeless Needled Suture in which both ends of the loop are securely attached into one end of a needle. Another idea developed by ETHICON in answer to a surgical challenge.



MEETING THE CHALLENGE

Suture requirements and wound closure techniques are constantly subject to re-evaluation and change. At ETHICON we are very much a part of this process and welcome the challenge it offers. We put our considerable research, development and manufacturing resources to work to produce still better needle designs and suture materials.

ETHICON TRADEMARK

SERVICE TO SURGERY

ETHICON LTD., Bankhead Avenue, Edinburgh EH11 4HE, Scotland


Pre-operative Aminoplex 5 appears to reduce morbidity
800 kilocals not enough
99% utilisation
0.25 mg per kg body-weight per 24 hours
3 days: too late
A significant reduction in post-operative infection
0.25 mg per kilo
Aminop

Nutrition: recovery

"The practical advantage of intravenous feeding solutions which contain amino acids and calorie source in the same bottle is that of simplicity. The use of a 'one bottle' solution does not remove the responsibility for assessing the requirements of a patient, **neither does it prevent the meeting of those requirements**"

— a principle supported by more biochemistry on more ill patients than any other regime of parenteral nutrition



lex 5

Geistlich

Geistlich Chester
Newton Bank
Long Lane
Chester CH2 3QZ

Telephone
Chester 47534

ACTA GASTRO-ENTEROLOGICA BELGICA

Organe de la Société belge de Gastro-entérologie

SOMMAIRE du FASCICULE 3–4 de 1977

Bibliographie

Acta gastro-enterologica belgica: 6 fascicules doubles par an.
Abonnements (Belgique et étranger): 1.500 Fr. b.
Le fascicule isolé: 250 Fr. b.
Secrétariat et rédaction: rue des Champs Elysées. 43.B 1050. Bruxelles. Belgique.